GSK706769 A First Time in Human Study For Males and Females

This study has been terminated.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00539201
First received: October 2, 2007
Last updated: October 13, 2010
Last verified: October 2010
  Purpose

To determine safety, tolerability and pharmacokinetics of GSK706769


Condition Intervention Phase
Healthy Subjects
Drug: GSK706769
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Blood levels of drug [ Time Frame: over 48 hours or 14 days. ]
  • Laboratory test results [ Time Frame: over 48 hours or 14 days ]
  • Vital signs [ Time Frame: over 48 hours or 14 days ]

Secondary Outcome Measures:
  • Effect of food on blood levels of drug [ Time Frame: over 48 hours ]
  • Effect of Kaletra on blood levels of drug [ Time Frame: over 48 hours ]
  • Effect of midazolam on drug levels [ Time Frame: over 12 hours ]
  • Plasma GSK706769 PK parameters, AUC(0-∞) or AUC(0-t), Cmax, tmax and tlag following single dose administration of a given dose of GSK706769 with and without high fat/calorie meal.
  • Plasma GSK706769 PK parameters, AUC(0-∞), AUC(0-t), Cmax, C12, and t1/2 following a single dose of GSK706769 with and without a single dose of LPV/RTV 400/100mg.
  • Safety parameters during LPV/RTV 400mg/100mg or high fat/calorie meal
  • Plasma AUC(0-∞) and CL/F of midazolam, a surrogate estimate of CYP3A enzyme activity, with and without GSK706769 co-administration.
  • Plasma GSK706769 PK parameters, AUC(0-∞) or AUC(0-t), Cmax, tmax and tlag, following single oral dose administered as tablet and solution.
  • Percentage and rate of change in CCR5 RO.
  • Day 14 GSK706769 AUC(0-τ) compared to Day 1 AUC(0-12) (if BID dosing) or Day 1 AUC(0-24) (if QD dosing) to estimate accumulation ratio (R) and GSK706769 AUC(0-τ) on Day 14 compared to AUC(0-∞) on Day 1 to evaluate time invariance
  • Pre-morning dose concentrations (Cτ) on Day 2 through 14 to assess the achievement of steady state of GSK706769 following repeat administration.
  • GSK706769 PK parameters: AUC(0-∞), AUC(0-t), and Cmax following single dose administration and AUC(0-τ), Cτ, and Cmax following repeat administration at different doses for the assessment of dose proportionality.

Enrollment: 34
Study Start Date: September 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: GSK706769
    Other Name: GSK706769
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The subject is healthy. Healthy, as judged by a responsible physician, with no clinically significant abnormality identified on the medical or laboratory evaluation, including 12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for this age group may be included only if the Investigator considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
  • The subject is ≥18 and ≤65 years of age.
  • The subject is male or female.
  • A female is eligible to enter and participate in this study if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who:

    • Has had a hysterectomy or
    • Has had a bilateral oophorectomy (removal of the ovaries) or
    • Has had a bilateral tubal ligation or
    • Is post-menopausal (a demonstration of total cessation of menses for ≥ 1 year from the date of screening visit). An FSH level will be performed to confirm a post-menopausal state. For this study FSH levels ≥ 40mIU/mL are consistent with menopause. If a subject is on estrogen replacement and menopausal status is questionable, estrogen replacement should be discontinued for 2 weeks and then the subject rescreened, as estrogen replacement can suppress FSH.
  • A male is eligible to enter and participate in the study if he is surgically sterile OR if he either agrees to abstain from sexual intercourse with a female partner or agrees to use a condom/spermicide, in addition to having his female partner use another form of contraception, such as an IUD, occlusive cap (diaphragm or cervical/vault cap) with spermicide, oral contraceptives, injectable progesterone, subdermal implants, female condom, contraceptive patch, or contraceptive vaginal ring, or has had a tubal ligation or hysterectomy. These criteria must be followed from the time of the first dose of study medication until 84 days after the last dose of study medication.
  • Body weight ≥ 50 kg (110 lbs.) for men and ≥ 45 kg (99 lbs.) for women and body mass index (BMI) between 18.5-29.9 kg/m2 inclusive.
  • A signed and dated written informed consent is obtained from the subject prior to screening.
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and is likely to complete the study as planned.

Exclusion Criteria:

  • As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unfit for the study.
  • The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects or 45-100bpm for male subjects.
  • History/evidence of symptomatic or asymptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting surgery or percutaneous transluminal coronary angioplasty or any clinically significant cardiac disease.
  • History/evidence of clinically significant pulmonary disease.
  • Has a positive pre-study Hepatitis B surface antigen; positive HCV antibody; or positive HIV-1 antibody result.
  • Has a history of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men (1 drink (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits) within 6 months of the screening visit.
  • Unwilling to abstain from alcohol for 72 hours prior to the start of dosing until collection of the final pharmacokinetic sample during each treatment period.
  • Has a history of regular use of tobacco- or nicotine-containing products within 3 months of the screening visit.
  • The subject has a positive pre-study drug and/or alcohol screen.
  • Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
  • The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Participation in the study would result in donation of blood in excess of 500 mL within a 56 day period.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. This includes subjects with a history of known or suspected sulfa related hypersensitivity. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled. Note: "Study" or "investigational" drugs includes GSK706769, placebo, lopinavir, ritonavir, midazolam, and flumazenil.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety.
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or serum creatinine values greater than the upper limit of normal or hemoglobin outside the normal range at screening. A single repeat is allowed for eligibility determination.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy should be excluded. Subjects with, or having a history of, gastritis or peptic ulcer disease should be excluded.
  • History of significant renal or hepatic diseases.
  • History of Gilbert's syndrome.
  • Subjects with a positive immunoassay fecal occult blood test prior to the start of dosing study drugs (repeat dose cohorts only)
  • Exclusion Criteria for:

    24-Hour Screening Holter:

    • Any symptomatic arrhythmia (except isolated extra systoles).
    • Sustained cardiac arrhythmias (such as atrial fibrillation or flutter, SVT, complete heart block).
    • Non-sustained or sustained ventricular tachycardia (defined as ≥ 3 consecutive ventricular ectopic beats).
    • Any conduction abnormality (including but not specific to left or right incomplete or complete bundle branch block, AV block [2nd degree or higher], WPW syndrome etc.).
    • Sinus Pauses >2.5 seconds.
    • 300 or more supraventricular ectopic beats in 24 hours.
    • 250 or more ventricular ectopic beats in 24 hours.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00539201

Locations
United States, Wisconsin
GSK Investigational Site
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00539201     History of Changes
Other Study ID Numbers: CRR110198
Study First Received: October 2, 2007
Last Updated: October 13, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
GSK706769,
CCR5 inhibitor,
HIV

ClinicalTrials.gov processed this record on September 22, 2014